ResultsIQ

ResultsIQ › Latest results › Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited Q2 FY26 results deck summary

NSE: JAGSNPHARM · BSE: 507789

Results deck of 3 Nov 2025, summarised by AI from the filing.

Jagsonpal H1FY26 revenue ₹1,501 Mn (+10.2% YoY) and PAT ₹234 Mn (+39.2% YoY); Q2 revenue steady at ₹745 Mn amid GST transition.

Key takeaways

  1. H1 growth H1FY26 revenue ₹1,501 Mn (H1FY25: ₹1,361 Mn, +10.2%) and PAT ₹234 Mn (H1FY25: ₹168 Mn, +39.2%).
  2. Guidance Plan to launch 4-6 niche, innovation-driven products annually, driving market engagement and revenue.
  3. Leadership Amrut Medhekar appointed COO and Nirav Vora appointed CFO to steer the next phase of growth.
  4. Risk Q2 EBITDA margin declined 39 bps YoY to 24.3% amid GST transition adjustments.

Original filing on BSE

Jagsonpal Pharmaceuticals Limited Q1 FY27 results

As filed: Revenue ₹82.2 cr (+8% year on year), EBITDA ₹17.2 cr (+33% year on year), PAT ₹13.2 cr (+20% year on year), EBITDA margin 21.0% (+386 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹64.2 cr (+9% year on year), EBITDA ₹11.2 cr (+40% year on year), PAT ₹8.8 cr (+25% year on year), EBITDA margin 17.4% (+382 bps). Score 38 of 100, Below trend. Revenue, EBITDA and profit growth were in line with the company's own trend. EBITDA margin rose 382 bps year on year. Other income 27% of PBT. Revenue fell 12% from last quarter. Share price after the results: +2.6% in 30 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹73.0 cr (−1% year on year), EBITDA ₹16.3 cr (+2% year on year), PAT ₹11.0 cr (+4% year on year), EBITDA margin 22.3% (+68 bps). Score 41 of 100, In line with trend. Revenue, EBITDA and profit before exceptional items growth were below the company's own trend. EBITDA margin rose 68 bps year on year. Share price after the results: +5.4% in 30 days (Nifty 500: +2.5%).
  • Q2 FY26: Revenue ₹74.0 cr (−1% year on year), EBITDA ₹16.0 cr (+7% year on year), PAT ₹13.0 cr (+18% year on year), EBITDA margin 21.6% (+162 bps). Score 41 of 100, In line with trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 162 bps year on year. Share price after the results: −4.7% in 30 days (Nifty 500: −0.4%).
  • Q1 FY26: Revenue ₹76.0 cr (+25% year on year), EBITDA ₹13.0 cr (+30% year on year), PAT ₹11.0 cr (+120% year on year), EBITDA margin 17.1% (+71 bps). Score 65 of 100, Above trend. Revenue and profit growth were above the company's own trend; EBITDA growth was below it. EBITDA margin rose 71 bps year on year. Share price after the results: −9.4% in 30 days (Nifty 500: +0.2%).
  • Q4 FY25: Revenue ₹59.0 cr (+37% year on year), EBITDA ₹8.0 cr (+167% year on year), PAT ₹7.0 cr (+75% year on year), EBITDA margin 13.6% (+658 bps). Score 57 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit growth was in line with it. EBITDA margin rose 658 bps year on year. Other income 33% of PBT. Revenue fell 20% from last quarter. Share price after the results: −2.8% in 30 days (Nifty 500: +4.5%).
  • Q3 FY25: Revenue ₹74.0 cr (+57% year on year), EBITDA ₹16.0 cr (+300% year on year), PAT ₹32.0 cr (+220% year on year), EBITDA margin 21.6% (+1,000 bps). Score 100 of 100, Above trend. EBITDA margin rose 1000 bps year on year. Not enough history for a trend yet: scored on growth alone.
  • Q2 FY25: Revenue ₹75.0 cr, EBITDA ₹15.0 cr, PAT ₹11.0 cr, EBITDA margin 20.0%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Jagsonpal Pharmaceuticals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.